The effects of pravastatin on serum adipocytokines in patients with IGT and metabolic syndrome

Objective To investigate the effects of pravastatin on the blood biochemical index,the levels of serum resistin,tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in patients with impaired glucose tolerance (IGT) and metabolic syndrome (MS).Methods 60 patients with IGT and MS were random treated with pravastatin or remedial life-style intervention,and the levels of lipids profiles,insulin resistance index (HOMA-IR),serum resistin,TNF-α and IL-6 were measured before and after treatment.Results The levels of total cholesterol [ (4.45 ±0.60)mmol/L vs (5.58 ±0.96) mmol/L,t =-5.42,P ＜0.01],HOMA-IR [3.22 ±0.64 vs 3.58 ±0.71,t =-2.05,P ＜0.05) ],resistin[ (1.97 ±0.72) μg/L vs (2.76 ±0.73) μg/L,t=-4.26,P ＜0.01 ],TNF-α[ (9.36 ±2.03) μg/L vs (13.87 ±2.30)μg/L,t =-8.06,P ＜0.01] and IL-6[ (3.50 ±0.99) μg/L vs (6.32 ±1.17) μg/L,t =-10.06,P ＜0.01 ] in pravastatin group were significantly lower than those in life-style intervention group.Conclusion Pravastatin could improve insulin sensitivity of the patients with IGT and MS,significantly decreased the serum levels of resistin,TNF-α,IL-6,and it had anti-inflammatory effect. Key words: Pravastatin/PD; Glucose intolerance/CO/DF/ME; Metabolic syndrome X/CO/DT/ME; Adipokines/ME